Gepotidacin shows promise for the treatment of uncomplicated gonorrhoea

Affiliations

¹ WHO Collaborating Centre for Gonorrhoea and other Sexually Transmitted Infections, Örebro University, Örebro, SE-701 85, Sweden; Institute for Global Health, University College London, London, UK. Electronic address: magnus.unemo@regionorebrolan.se.
² Global HIV, Hepatitis and STI Programmes, WHO, Geneva, Switzerland.

Comment

Magnus Unemo et al. Lancet. 2025.

. 2025 May 3;405(10489):1560-1562.

doi: 10.1016/S0140-6736(25)00680-4. Epub 2025 Apr 14.

¹ WHO Collaborating Centre for Gonorrhoea and other Sexually Transmitted Infections, Örebro University, Örebro, SE-701 85, Sweden; Institute for Global Health, University College London, London, UK. Electronic address: magnus.unemo@regionorebrolan.se.
² Global HIV, Hepatitis and STI Programmes, WHO, Geneva, Switzerland.

No abstract available

Conflict of interest statement

We declare no competing interests.

Oral gepotidacin for the treatment of uncomplicated urogenital gonorrhoea (EAGLE-1): a phase 3 randomised, open-label, non-inferiority, multicentre study.
Ross JDC, Wilson J, Workowski KA, Taylor SN, Lewis DA, Gatsi S, Flight W, Scangarella-Oman NE, Jakielaszek C, Lythgoe D, Powell M, Janmohamed S, Absalon J, Perry C. Ross JDC, et al. Lancet. 2025 May 3;405(10489):1608-1620. doi: 10.1016/S0140-6736(25)00628-2. Epub 2025 Apr 14. Lancet. 2025. PMID: 40245902 Clinical Trial.